Proton pump inhibitor use and pancreatic risk: evidence from the UK biobank participants and animal experiments.

ABSTRACT:

Introduction

Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders and are often used empirically in patients with pancreatic disease, yet their long-term impact on pancreatic health remains unclear. We evaluated whether regular PPI use is associated with risks of acute pancreatitis (AP), chronic pancreatitis (CP), and pancreatic cancer (PC).

Methods

We analyzed 489,394 UK Biobank participants aged 38-73 years, comparing regular PPI users with non-users and with histamine-2 receptor antagonist (H₂RA) users as an active comparator. Associations with incident pancreatic outcomes were estimated using Cox regression models, landmark analysis, and propensity score matching, supplemented by multiple sensitivity analyses, including stratified

SUBMITTER: Gao X 

PROVIDER: S-EPMC12540142 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature